Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has made significant investments in wealth management products across multiple banks, including Industrial Bank, CZB, CMB, and CITIC, with a total outstanding principal amounting to RMB1.5 billion. These strategic financial maneuvers are aimed at optimizing the company’s asset management and liquidity, potentially impacting its operational flexibility and financial stability in the competitive biopharmaceutical sector.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company focuses on the development and distribution of biopharmaceutical products, leveraging strategic investments in wealth management to enhance its financial positioning.
Average Trading Volume: 675,106
Technical Sentiment Signal: Buy
Current Market Cap: HK$76.73B
Find detailed analytics on 6990 stock on TipRanks’ Stock Analysis page.